Citations

Clear

1526 citation(s) found for "Sun, Bo".

P3–098: Effect of measurement variability on hippocampal volume–based clinical trial enrichment
Yu, Peng , Sun, Jia, Wolz, Robin, Stephenson, Diane , Cole, Patricia E., Hill, David , Schwarz, Adam J. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2013.05.1168 Get It

O2–10–06: Neuropathological outcome of prospectively followed normal elderly brain bank volunteers
Hentz, Joseph G. , Adler, Charles, Shill, Holly A. , Jacobson, Sandra A. , Caviness, John N., Belden, Christine M. , Driver‐Dunckley, Erika, Davis, Kathryn, Sue, Lucia I., Beach, Thomas G. , Dugger, Brittany N. , Sabbagh, Marwan Noel , Driver‐Dunckley, Erika

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2013.04.194 Get It

Contribution of Bcl-2 Phosphorylation to Bak Binding and Drug Resistance
Dai, Haiming , Ding, Husheng, Meng, X. Wei, Lee, Sun Hee , Schneider, Paula A., Kaufmann, Scott H. , Dai, Haiming , Lee, Sun-Hee

Mayo Clinic

Cancer Research | October 5, 2013 | Volume: 73 | Issue: 23 | Pages: 6998-7008

10.1158/0008-5472.can-13-0940 | PMID 24097825 Get It

Abstract Bcl-2 is phosphorylated on Ser70 after treatment of cells with spindle poisons. On the basis of effects observed in cells overexpressing Bcl-2 S70E or S70A mutants, various studies have concluded that Ser70 phosphorylation either enhances or diminishes Bcl-2 function. In the present study, the ability of phosphorylated Bcl-2, as well as the S70E and S70A mutants, to bind and neutralize proapoptotic Bcl-2 family members under cell-free conditions and in intact cells was examined in an attempt to resolve this controversy. Surface plasmon resonance indicated that phosphorylated Bcl-2, Bcl-2 S70E, and Bcl-2 S70A exhibit enhanced binding to Bim and Bak compared with unmodified Bcl-2. This enhanced binding reflected a readily detectable conformation change in the loop domain of Bcl-2. Furthermore, Bcl-2 S70E and S70A bound more Bak and Bim than wild-type Bcl-2 in pull-downs and afforded greater protection against several chemotherapeutic agents. Importantly, binding of endogenous Bcl-2 to Bim also increased during mitosis, when Bcl-2 is endogenously phosphorylated, and disruption of this mitotic Bcl-2/Bim binding with navitoclax or ABT-199, like Bcl-2 downregulation, enhanced the cytotoxicity of paclitaxel. Collectively, these results provide not only a mechanistic basis for the enhanced antiapoptotic activity of phosphorylated Bcl-2, but also an explanation for the ability of BH3 mimetics to enhance taxane sensitivity. Cancer Res; 73(23); 6998–7008. ©2013 AACR.
Improving Survival in Acute Myeloid Leukemia: Pick the Best Subjects?
Litzow, Mark R. , Lazarus, Hillard M. , Gale, Robert Peter

Mayo Clinic

Journal of Clinical Oncology | September 24, 2013 | Volume: 31 | Issue: 31 | Pages: 3854-3856

10.1200/jco.2013.52.0296 | PMID 24062404 Get It

Impact of peri‐operative blood transfusion on the outcomes of patients undergoing radical cystectomy for urothelial carcinoma of the bladder
Kluth, Luis A. , Xylinas, Évanguelos , Rieken, Malte, Ghouayel, Maya El, Sun, Maxine , Karakiewicz, Pierre I. , Boorjian, Stephen A. , Lee, Richard K. , Briganti, Alberto , Fisch, Margit , Scherr, Douglas S. , Lotan, Yair , Chun, Felix K.‐H. , Rouprêt, Morgan , Shariat, Shahrokh F.

Mayo Clinic

BJU International | September 5, 2013 | Volume: 113 | Issue: 3 | Pages: 393-398

10.1111/bju.12439 | PMID 24053618 Get It

Objective To determine the association between peri‐operative blood transfusion ( PBT ) and oncological outcomes in a large multi‐institutional cohort of patients undergoing radical cystectomy ( RC ) for urothelial carcinoma of the bladder ( UCB ). Patients and Methods We conducted a retrospective analysis of 2895 patients treated with RC for UCB . Univariable and multivariable C ox regression models were used to analyse the effect of PBT administration on disease recurrence, cancer‐specific mortality, and any‐cause mortality. Results Patients' median (interquartile range [ IQR ]) age was 67 (60, 73) years and the median ( IQR ) follow‐up was 36.1 (15, 84) months. Patients who received PBT were more likely to have advanced disease ( P < 0.001), high grade tumours ( P = 0.047) and nodal metastasis ( P = 0.004). PBT was associated with a higher risk of disease recurrence ( P = 0.003), cancer‐specific mortality ( P = 0.017), and any‐cause mortality ( P = 0.010) in univariable, but not multivariable, analyses ( P > 0.05). In multivariable analyses, pathological tumour stage, pathological nodal stage, soft tissue surgical margin, lymphovascular invasion and administration of adjuvant chemotherapy were independent predictors of disease recurrence, cancer‐specific mortality and any‐cause mortality (all P values <0.002). Conclusions Patients with UCB who underwent RC and received PBT had a greater risk of disease recurrence, cancer‐specific mortality and any‐cause mortality in univariable, but not multivariable, analysis. Although the greater need for PBT with more advanced disease is probably caused by a number of factors, including surgical and cancer‐related factors, the present analysis showed that the disease characteristics rather than need for PBT led to worse outcomes.
Early Experience of Pre- and Post-Contrast 7.0T MRI in Brain Tumors
Paek, Seung Leal, Chung, Young Seob , Paek, Sun Ha , Hwang, Jae Ha , Sohn, Chul‐Ho , Choi, Seung Hong , Son, Young‐Don , Kim, Young-Bo , Kim, Dong Gyu , Lee, Kendall H. , Cho, Zang‐Hee

Mayo Clinic

Journal of Korean Medical Science | September 2, 2013 | Volume: 28 | Issue: 9 | Pages: 1362

10.3346/jkms.2013.28.9.1362 | PMID 24015044 Get It

Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma
Smith, Sonali M. , Burns, Linda J. , He, Wensheng , Fenske, Timothy S. , Suzuki, Ritsuro , Hsu, Jack W., Schouten, Harry C. , Hale, Gregory A., Holmberg, Leona , Sureda, Anna , Freytes, César O. , Inwards, David J. , Gross, Thomas G. , Cairo, Mitchell S. , Costa, Luciano J. , Wiernik, Peter H. , Maharaj, Dipnarine , Laport, Ginna G. , Montoto, Silvia , Hari, Parameswaran , Holmberg, Leona , Besien, Koen van , Le‐Rademacher, Jennifer , Maziarz, Richard Thomas , Gale, Robert Peter , Lazarus, Hillard M. , Montoto, Silvia , Costa, Luciano J , Hari, Parameswaran

Mayo Clinic

Journal of Clinical Oncology | July 30, 2013 | Volume: 31 | Issue: 25 | Pages: 3100-3109

10.1200/jco.2012.46.0188 | PMID 23897963 Get It

Purpose To analyze outcomes of hematopoietic cell transplantation (HCT) in T-cell non-Hodgkin lymphoma. Patients and Methods Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell lymphoma not otherwise specified, 27 angioimmunoblastic T-cell lymphoma) undergoing autologous HCT (autoHCT; n = 115; median age, 43 years) or allogeneic HCT (alloHCT; n = 126; median age, 38 years) were analyzed. Primary outcomes were nonrelapse mortality (NRM), relapse/progression, progression-free survival (PFS), and overall survival (OS). Patient, disease, and HCT-related variables were analyzed in multivariate Cox proportional hazard models to determine association with outcomes. Results AutoHCT recipients were more likely in first complete remission (CR1; 35% v 14%; P = .001) and with chemotherapy-sensitive disease (86% v 60%; P < .001), anaplastic large-cell histology (53% v 40%; P = .04), and two or fewer lines of prior therapy (65% v 44%; P < .001) compared with alloHCT recipients. Three-year PFS and OS of autoHCT recipients beyond CR1 were 42% and 53%, respectively. Among alloHCT recipients who received transplantations beyond CR1, 31% remained progression-free at 3 years, despite being more heavily pretreated and with more refractory disease. NRM was 3.5-fold higher (95% CI, 1.80 to 6.99; P < .001) for alloHCT. In multivariate analysis, chemotherapy sensitivity (hazard ratio [HR], 1.8; 95% CI, 1.16 to 2.87) and two or fewer lines of pretransplantation therapy (HR, 5.02; 95% CI, 2.15 to 11.72) were prognostic of survival. Conclusion These data describe the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness earlier in the disease course, and limited utility in multiply relapsed disease. Notably, autoHCT at relapse may be a potential option for select patients, particularly those with anaplastic large-cell lymphoma histology.
Impact of Plaque Composition on Long-Term Clinical Outcomes in Patients with Coronary Artery Occlusive Disease
Kim, Wan Ho, Park, Hyun Woong , Song, In Girl, Yang, Dong Ju, Seo, Young Hoon , Yuk, Hyung Bin, Park, Yohan , Kwon, Taek‐Geun , Rihal, Charanjit S. , Lee, Moo-Sik, Bae, Jang‐Ho , Kim, Ki Hong , Rihal, Charanjit S. , Lerman, Amir

Mayo Clinic

Korean Circulation Journal | July 19, 2013 | Volume: 43 | Issue: 6 | Pages: 377

10.4070/kcj.2013.43.6.377 | PMID 23882286 Get It

Autologous haematopoietic cell transplantation for non‐Hodgkin lymphoma with secondary CNS involvement
Wang, Zhiwei , Zhang, Mei‐Jie , Bolwell, Brian J., Chen, Andy I. , Fenske, Timothy S. , Freytes, César O. , Gibson, John, Hayes‐Lattin, Brandon , Holmberg, Leona , Inwards, David J. , Isola, Luis , Khoury, H. Jean , Lewis, Victor , Maharaj, Dipnarine , Munker, Reinhold , Phillips, Gordon L., Rizzieri, David A. , Rowlings, Philip A., Saber, Wael , Satwani, Prakash , Waller, Edmund K. , Maloney, David G. , Montoto, Silvia , Laport, Ginna G. , Hari, Parameswaran , Holmberg, Leona , Chen, Andy , Maziarz, Richard Thomas , Gale, Robert Peter , Vose, Julie M. , Lazarus, Hillard M. , Waller, Edmund K , Montoto, Silvia , Hari, Parameswaran

Mayo Clinic

British Journal of Haematology | July 6, 2013 | Volume: 162 | Issue: 5 | Pages: 648-656

10.1111/bjh.12451 | PMID 23829536 Get It

SummaryPre‐existing central nervous system (CNS) involvement may influence referral for autologous haematopoietic cell transplantation (AHCT) for patients with non‐Hodgkin lymphoma (NHL). The outcomes of 151 adult patients with NHL with prior secondary CNS involvement (CNS+) receiving an AHCT were compared to 4688 patients without prior CNS lymphoma (CNS−). There were significant baseline differences between the cohorts. CNS+ patients were more likely to be younger, have lower performance scores, higher age‐adjusted international prognostic index scores, more advanced disease stage at diagnosis, more aggressive histology, more sites of extranodal disease, and a shorter interval between diagnosis and AHCT. However, no statistically significant differences were identified between the two groups by analysis of progression‐free survival (PFS) and overall survival (OS) at 5 years. A matched pair comparison of the CNS+ group with a subset of CNS− patients matched on propensity score also showed no differences in outcomes. Patients with active CNS lymphoma at the time of AHCT (n = 55) had a higher relapse rate and diminished PFS and OS compared with patients whose CNS lymphoma was in remission (n = 96) at the time of AHCT. CNS+ patients can achieve excellent long‐term outcomes with AHCT. Active CNS lymphoma at transplant confers a worse prognosis.